BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33000256)

  • 41. MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.
    Oudin MJ; Barbier L; Schäfer C; Kosciuk T; Miller MA; Han S; Jonas O; Lauffenburger DA; Gertler FB
    Mol Cancer Ther; 2017 Jan; 16(1):143-155. PubMed ID: 27811011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
    Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
    Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Troponin T1 silencing inhibits paclitaxel resistance and the development of breast cancer via suppressing rat sarcoma virus/rapidly accelerated fibrosarcoma 1 pathway.
    Zhu T; Zhou P; Yang L; Fang X; Zhi X
    Environ Toxicol; 2024 Apr; 39(4):2064-2076. PubMed ID: 38095131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting claudin-4 enhances chemosensitivity in breast cancer.
    Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
    Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
    Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
    Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
    Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
    Tao L; Wu YQ; Zhang SP
    Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.
    Chen L; Yuan Y; Kar S; Kanchi MM; Arora S; Kim JE; Koh PF; Yousef E; Samy RP; Shanmugam MK; Tan TZ; Shin SW; Arfuso F; Shen HM; Yang H; Goh BC; Park JI; Gaboury L; Lobie PE; Sethi G; Lim LHK; Kumar AP
    Mol Cancer Ther; 2017 Nov; 16(11):2528-2542. PubMed ID: 29021293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.
    Cai J; Chen S; Zhang W; Hu S; Lu J; Xing J; Dong Y
    Phytomedicine; 2014 Jun; 21(7):984-91. PubMed ID: 24680370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.
    Li CY; Miao KL; Chen Y; Liu LY; Zhao GB; Lin MH; Jiang C
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6008-6014. PubMed ID: 30280784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells.
    Mao Y; Li W; Hua B; Gu X; Pan W; Chen Q; Xu B; Wang Z; Lu C
    Biomed Res Int; 2020; 2020():2406159. PubMed ID: 32104682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. +TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.
    Thomas GE; Sreeja JS; Gireesh KK; Gupta H; Manna TK
    Int J Oncol; 2015 Jan; 46(1):133-46. PubMed ID: 25310526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth differentiation factor 15 is required for triple-negative breast cancer cell growth and chemoresistance.
    He Y; Zhang X; Zhang Y; Luo W; Zhu Z; Song K; Shi J
    Anticancer Drugs; 2023 Mar; 34(3):351-360. PubMed ID: 36729006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.